Literature DB >> 29574756

Oxycodone-induced tolerance to respiratory depression: reversal by ethanol, pregabalin and protein kinase C inhibition.

Rob Hill1, William L Dewey2, Eamonn Kelly1, Graeme Henderson1.   

Abstract

BACKGROUND AND
PURPOSE: Oxycodone, a prescription opioid, is a major drug of abuse, especially in the USA, and contributes significantly to opioid overdose deaths each year. Overdose deaths result primarily from respiratory depression. We have studied respiratory depression by oxycodone and have characterized how tolerance develops on prolonged exposure to the drug. We have investigated the role of PKC in maintaining tolerance and have examined whether ethanol or pregabalin reverses oxycodone-induced tolerance. EXPERIMENTAL APPROACH: Respiration was measured in male CD-1 mice by whole-body plethysmography. Mice were preinjected with oxycodone then implanted with mini-pumps (s.c.) delivering 20, 45 or 120 mg·kg-1 ·day-1 oxycodone for 6 days and subsequently challenged with oxycodone (3 mg·kg-1 , i.p.) or morphine (10 mg·kg-1 , i.p.) to assess the level of tolerance. KEY
RESULTS: Oxycodone-treated mice developed tolerance to oxycodone and cross tolerance to morphine-induced respiratory depression. Tolerance was less with 20 mg·kg-1 ·day-1 than with 45 or 120 mg·kg-1 ·day-1 oxycodone treatment. At doses that do not depress respiration, ethanol (0.3 g·kg-1 ), pregabalin (20 mg·kg-1 ) and calphostin C (45 μg·kg-1 ) all reversed oxycodone-induced tolerance resulting in significant respiratory depression. Reversal of tolerance was less in mice treated with oxycodone (120 mg·kg-1 ·day-1 ). In mice receiving ethanol and calphostin C or ethanol and pregabalin, there was no greater reversal of tolerance than seen with either drug alone. CONCLUSION AND IMPLICATIONS: These data suggest that oxycodone-induced tolerance is mediated by PKC and that reversal of tolerance by ethanol or pregabalin may be a contributory factor in oxycodone overdose deaths.
© 2018 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29574756      PMCID: PMC5980627          DOI: 10.1111/bph.14219

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  57 in total

1.  Time course of changes in breathing pattern in morphine- and oxycodone-induced respiratory depression.

Authors:  K Leino; L Mildh; K Lertola; T Seppälä; O Kirvelä
Journal:  Anaesthesia       Date:  1999-09       Impact factor: 6.955

Review 2.  Abuse and Misuse of Pregabalin and Gabapentin.

Authors:  Kirk E Evoy; Megan D Morrison; Stephen R Saklad
Journal:  Drugs       Date:  2017-03       Impact factor: 9.546

3.  Opioid overdose leading to intensive care unit admission: Epidemiology and outcomes.

Authors:  Gregory J Pfister; Robert M Burkes; Brian Guinn; Jacquelene Steele; Robert R Kelley; Timothy L Wiemken; Mohamed Saad; Julio Ramirez; Rodrigo Cavallazzi
Journal:  J Crit Care       Date:  2016-04-30       Impact factor: 3.425

4.  Levels and correlates of polydrug use among heroin users and regular amphetamine users.

Authors:  S Darke; W Hall
Journal:  Drug Alcohol Depend       Date:  1995-10       Impact factor: 4.492

5.  Determination of the role of conventional, novel and atypical PKC isoforms in the expression of morphine tolerance in mice.

Authors:  Forrest L Smith; Bichoy H Gabra; Paul A Smith; Marcia C Redwood; William L Dewey
Journal:  Pain       Date:  2006-09-11       Impact factor: 6.961

6.  Drug Overdose Deaths in the United States, 1999-2015.

Authors:  Holly Hedegaard; Margaret Warner; Arialdi M Minino
Journal:  NCHS Data Brief       Date:  2017-02

7.  Ethanol reversal of cellular tolerance to morphine in rat locus coeruleus neurons.

Authors:  Javier Llorente; Sarah Withey; Guadalupe Rivero; Margaret Cunningham; Alex Cooke; Kunal Saxena; Jamie McPherson; Sue Oldfield; William L Dewey; Chris P Bailey; Eamonn Kelly; Graeme Henderson
Journal:  Mol Pharmacol       Date:  2013-05-28       Impact factor: 4.436

8.  Abuse of Gabapentin is Associated with Opioid Addiction.

Authors:  Leo Bastiaens; James Galus; Cherise Mazur
Journal:  Psychiatr Q       Date:  2016-12

Review 9.  Heroin overdose: research and evidence-based intervention.

Authors:  Shane Darke; Wayne Hall
Journal:  J Urban Health       Date:  2003-06       Impact factor: 3.671

10.  Reversal of morphine analgesic tolerance by ethanol in the mouse.

Authors:  L C Hull; B H Gabra; C P Bailey; G Henderson; W L Dewey
Journal:  J Pharmacol Exp Ther       Date:  2013-03-25       Impact factor: 4.030

View more
  13 in total

1.  Quantifying enhanced risk from alcohol and other factors in polysubstance-related deaths.

Authors:  Zheng Dai; Marie A Abate; D Leann Long; Gordon S Smith; Theresa M Halki; James C Kraner; Allen R Mock
Journal:  Forensic Sci Int       Date:  2020-05-31       Impact factor: 2.395

2.  Oxycodone-induced tolerance to respiratory depression: reversal by ethanol, pregabalin and protein kinase C inhibition.

Authors:  Rob Hill; William L Dewey; Eamonn Kelly; Graeme Henderson
Journal:  Br J Pharmacol       Date:  2018-05-07       Impact factor: 8.739

Review 3.  Updated Clinical Pharmacokinetics and Pharmacodynamics of Oxycodone.

Authors:  Mari Kinnunen; Panu Piirainen; Hannu Kokki; Pauliina Lammi; Merja Kokki
Journal:  Clin Pharmacokinet       Date:  2019-06       Impact factor: 6.447

4.  Prevalence of and Factors Associated with Gabapentinoid Use and Misuse Among Texas Medicaid Recipients.

Authors:  Elizabeth A Ibiloye; Jamie C Barner; Kenneth A Lawson; Karen L Rascati; Kirk E Evoy; Alyssa M Peckham
Journal:  Clin Drug Investig       Date:  2021-02-12       Impact factor: 2.859

5.  Mice with high FGF21 serum levels had a reduced preference for morphine and an attenuated development of acute antinociceptive tolerance and physical dependence.

Authors:  Louben Dorval; Brian I Knapp; Olufolake A Majekodunmi; Sophia Eliseeva; Jean M Bidlack
Journal:  Neuropharmacology       Date:  2021-10-26       Impact factor: 5.250

6.  Respiratory depressant effects of fentanyl analogs are opioid receptor-mediated.

Authors:  Neil B Varshneya; Sherif H Hassanien; Melissa C Holt; David L Stevens; Nathan K Layle; Jonathon R Bassman; Donna M Iula; Patrick M Beardsley
Journal:  Biochem Pharmacol       Date:  2021-10-19       Impact factor: 6.100

7.  Global patterns of opioid use and dependence: harms to populations, interventions, and future action.

Authors:  Louisa Degenhardt; Jason Grebely; Jack Stone; Matthew Hickman; Peter Vickerman; Brandon D L Marshall; Julie Bruneau; Frederick L Altice; Graeme Henderson; Afarin Rahimi-Movaghar; Sarah Larney
Journal:  Lancet       Date:  2019-10-23       Impact factor: 79.321

Review 8.  Understanding and countering opioid-induced respiratory depression.

Authors:  Jordan T Bateman; Sandy E Saunders; Erica S Levitt
Journal:  Br J Pharmacol       Date:  2021-06-05       Impact factor: 8.739

9.  Sexually dimorphic neuroimmune response to chronic opioid treatment and withdrawal.

Authors:  Mohit Kumar; Jennifer R Rainville; Kori Williams; Joshua A Lile; Georgia E Hodes; Fair M Vassoler; Jill R Turner
Journal:  Neuropharmacology       Date:  2021-01-22       Impact factor: 5.250

10.  Fentanyl depression of respiration: Comparison with heroin and morphine.

Authors:  Rob Hill; Rakulan Santhakumar; William Dewey; Eamonn Kelly; Graeme Henderson
Journal:  Br J Pharmacol       Date:  2019-12-23       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.